Peptide cycling: when to cycle, when to run continuously

Guide 7 min read Reviewed

Not all peptides need cycling. A breakdown of which compounds benefit from cycling protocols, which are typically run continuously, and the reasoning behind each approach.

Contents8
  1. 1What is cycling?
  2. 2Why cycle?
  3. 3Compounds that commonly benefit from cycling
  4. 4Compounds typically run continuously
  5. 5Designing a cycle
  6. 6Reading your body: signs of desensitisation
  7. 7Frequently asked questions
  8. 8References

A frequent question in peptide communities is "do I need to cycle this?" The answer depends on the compound, how it works, and what the break is meant to do. For most research peptides, cycling patterns come from community practice rather than trials, and this guide says where that is the case.

This guide covers the reasoning behind cycling, which compound classes it is used with, which are run without breaks, and how to track a cycle.

What is cycling?

Cycling means planned periods of use ("on") alternating with planned breaks ("off"). The practice comes from anabolic steroid use. With peptides it is less settled: some compounds raise questions about receptor desensitisation, and others are given continuously in their trials.

The terminology is straightforward:

  • On period: The duration of active compound use. May be measured in days (e.g., 5 days on) or weeks (e.g., 8 weeks on).
  • Off period: The break between active cycles. Intended to allow receptor resensitisation, physiological recovery, or both.
  • Cycle length: The total duration of one complete on + off rotation.
  • Loading phase: Some compounds use a higher-frequency or higher-dose initial period before transitioning to a maintenance protocol. This is distinct from cycling: loading establishes a baseline, while cycling alternates between use and rest.

Cycling is distinct from titration (gradually increasing dose) and from course-based use (running a compound for a set duration to address a specific condition, then stopping). A course of BPC-157 for an injury is not cycling; it is goal-driven use with a defined endpoint. Cycling implies a repeating on/off pattern.

Why cycle?

The reasons for cycling vary by compound class, but they generally fall into four categories:

  • Receptor desensitisation (downregulation): repeated stimulation of some receptors can reduce the response to the same dose. For GHRP-2, studies of chronic dosing in humans found that whether the GH response becomes desensitised depends in part on the dose and how often it is given.1
  • Physiological strain management: some compounds stress organs or metabolism during use. High doses of 17-alpha-alkyl androgens, mostly oral, are linked to liver tumours on the Depo-Testosterone label, and MK-677 lowered insulin sensitivity in a 2-year trial.64 A break limits continuous exposure.
  • Maintaining sensitivity: some users report that periodic breaks keep a compound feeling effective. For most peptide classes this is anecdotal, not shown in trials.
  • Cost: where continuous use gives diminishing returns, breaks reduce the total amount used.

Compounds that commonly benefit from cycling

These compounds are most often cycled in community protocols. The on and off periods are community patterns, not trial or label schedules; the last column gives what the evidence says.

Compound Typical on Typical off Reason and evidence
Ipamorelin 5 days 2 days Receptor sensitivity; no human cycling trial. Acts through a GHRP-like receptor.2
GHRP-2 / GHRP-6 5 days 2 days Desensitisation with chronic GHRP-2 depends partly on dose and frequency.1
CJC-1295 (no DAC) 5 days 2 days Receptor sensitivity; no human trial of this form found.
MK-677 (Ibutamoren) 8-12 weeks 4-8 weeks Insulin sensitivity fell and fasting glucose rose in a 2-year trial.4
Melanotan II Loading: 2-3 weeks Maintenance: as needed Melanocortin receptor sensitivity; FDA notes case reports of serious adverse events.5
Hexarelin 4-8 weeks 4 weeks Desensitisation concern; no source opened for this page.
Oral AAS (e.g., Anavar, Dianabol) 6-8 weeks Equal or longer Liver risk with high-dose 17-alpha-alkyl androgens.6

GH secretagogues: the desensitisation question

For GH secretagogues, the human evidence on desensitisation is limited. In studies giving GHRP-2, GHRH or both to normal men and women for 7 to 30 days, chronic dosing changed how the two combined, and whether the GH response became desensitised depended in part on dose and frequency.1 Ipamorelin acts through the same GHRP-like receptor as GHRP-6.2 No trial of on/off cycling with these peptides was found.

The two most common community patterns for GH peptides are:

  • 5 on / 2 off (daily): five days of dosing and two rest days each week, often weekdays on and weekends off, used with ipamorelin, GHRP-2 and CJC-1295 (no DAC). The idea is that two rest days a week are enough recovery; no trial tested it.
  • 8-12 weeks on / 4 weeks off: a longer cycle with a bigger break, used more with MK-677, where the 2-year trial found lower insulin sensitivity and higher fasting glucose, and with hexarelin.4

CJC-1295 with DAC is different. Its estimated half-life in healthy adults was 5.8 to 8.1 days, and after repeated doses mean IGF-I stayed above baseline for up to 28 days.3 So it gives continuous stimulation whatever the injection pattern, and is often run once or twice a week without a traditional cycle.

Melanocortin agonists

Melanotan II acts on the melanocortin receptor system. The community pattern is a loading phase of daily doses for 2-3 weeks, then much less frequent maintenance doses. The FDA notes published case reports of serious adverse events with Melanotan II, including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.5

Oral compounds

Oral anabolic compounds (Anavar, Dianabol and similar 17-alpha-alkylated compounds) are almost always cycled. The Depo-Testosterone label notes that prolonged high doses of androgens, principally the 17-alpha-alkyl androgens, have been associated with hepatic adenomas, hepatocellular carcinoma and peliosis hepatis.6 Community cycles are typically 6-8 weeks with an equal or longer break, with liver panels and lipids checked around them.

Compounds typically run continuously

Several commonly used compounds are given continuously in their trials and labels.

GLP-1 receptor agonists

Semaglutide, tirzepatide, and retatrutide are not usually cycled. Their trials and labels are built on continuous weekly dosing, and STEP 1 described a sustained weight reduction over 68 weeks of continued semaglutide.713

GLP-1 discontinuation

Weight regain after stopping has been measured: in the STEP 1 extension, participants regained two-thirds of their prior weight loss one year after stopping semaglutide, and the authors concluded ongoing treatment is required to maintain the improvements.8 That is one reason continuous use, not cycling, is the usual pattern.

TRT (testosterone replacement)

Testosterone replacement therapy is continuous by design: it keeps testosterone in the normal range in people whose own production is insufficient, with ongoing monitoring.9 Stopping it brings back the original deficiency. This is distinct from performance "blast and cruise" protocols.

Healing peptides (BPC-157, TB-500)

BPC-157 and TB-500 are usually run as defined courses rather than cycled. Preclinical studies suggest BPC-157 acts on pathways in cell growth and angiogenesis and reduces inflammatory cytokines; no human data on desensitisation, or on course length, was found.10

GHK-Cu

GHK-Cu is used continuously for skin, or in courses for wound healing. A review describes GHK modulating collagen synthesis and breakdown and many genes; no study of desensitisation was found.11 Some users take breaks for cost.

Designing a cycle

Where a cycle is used, a planned structure is easier to read than arbitrary breaks. These are the main decisions.

1

Define the goal and select the compound

The goal decides whether cycling applies. Healing is usually a defined course; GH peptides are often cycled in community practice; GLP-1 weight management is continuous in the trials. See the stacking guide for combinations.

2

Choose the on/off structure

For GH secretagogues, 5 on / 2 off is the most common community starting point; for MK-677 and hexarelin, 8-12 weeks on and 4-8 weeks off is more typical. If downregulation develops over weeks, recovery would be expected to take weeks too, though no trial measured it for these peptides.

3

Plan bloodwork around the cycle

For GH peptides, IGF-1 at baseline, during the on period and after a break shows whether the compound is raising GH and whether the break returns levels to baseline; a review describes IGF-1 as a stable indication of integrated GH secretion.12 For oral compounds, liver panels and lipids before, during and after the cycle track liver strain.

4

Track subjective markers during and after

Daily subjective tracking (sleep, energy, recovery, appetite) complements periodic bloodwork. The pattern to look for: steady or improving markers on, a dip off, and recovery when the next on period starts. Markers that do not change across a break suggest the compound was contributing little.

Reading your body: signs of desensitisation

Desensitisation, where it happens, is gradual: a slow fading of effect despite consistent dosing and checked product. Spotting the pattern early allows a planned break rather than weeks of diminishing returns.

For GH secretagogues, desensitisation might show as:

  • Sleep quality improvements that were present in weeks 1-4 gradually diminishing
  • Reduced subjective recovery benefit from training
  • IGF-1 that rose early falling back toward baseline despite continued dosing, the most objective sign
  • A plateau in body composition changes that were previously progressing

For melanocortin agonists, desensitisation may present as:

  • Reduced tanning response from the same dose
  • Diminished appetite-suppressive effects
  • Reduced libido effects compared to initial use

The key distinction is gradual onset. A sudden loss of effect from one day to the next is more likely a product problem (degradation, contamination) or a dosing error than desensitisation. Daily tracking shows a gradual trend in the data before it is obvious in how things feel. For more, see why peptides might not be working.

When in doubt

One way to find out whether a break matters is to take one and watch the markers. If they fall during the break and recover on resuming, the compound was contributing and the cycle structure fits. If they stay the same, the compound may be contributing little at that dose.

Frequently asked questions

Do GLP-1 agonists like semaglutide need to be cycled?

GLP-1 receptor agonists such as semaglutide and tirzepatide are not usually cycled; their trials and labels use continuous weekly dosing.713 In the STEP 1 extension, participants regained two-thirds of their prior weight loss within a year of stopping semaglutide.8

How long should you cycle off GH peptides?

The common community patterns are 5 on / 2 off each week, or 8-12 weeks on and about 4 weeks off. No trial tested either for these peptides. Human studies of chronic GHRP-2 found that desensitisation depends in part on dose and frequency, and MK-677 lowered insulin sensitivity over 2 years, which is the usual reason it is cycled in longer blocks.14

What are the signs of receptor desensitisation?

A gradual fading of effect despite consistent dosing and checked product. For GH secretagogues, that might be smaller sleep or recovery benefits, stalled body composition, or, most objectively, IGF-1 falling back toward baseline.12 A sudden loss from one day to the next points more to product or dosing problems.

Does BPC-157 need to be cycled?

BPC-157 is not usually cycled; it is run as a defined course and stopped once the goal is met. No human data on desensitisation or course length was found: of 36 studies in a 2025 systematic review, 35 were preclinical.10

References

  1. Bowers CY et al. GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans. J Pediatr Endocrinol Metab. 1996. pubmed.ncbi.nlm.nih.gov
  2. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. pubmed.ncbi.nlm.nih.gov
  3. Teichman SL et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006. pubmed.ncbi.nlm.nih.gov
  4. Nass R et al. Effects of an oral ghrelin mimetic (MK-677) on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008. pubmed.ncbi.nlm.nih.gov
  5. US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 April 2026). 2026. fda.gov
  6. Pharmacia & Upjohn (DailyMed). Depo-Testosterone (testosterone cypionate) injection label. 2026. dailymed.nlm.nih.gov
  7. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. pubmed.ncbi.nlm.nih.gov
  8. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022. pubmed.ncbi.nlm.nih.gov
  9. Bhasin S et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018. pubmed.ncbi.nlm.nih.gov
  10. Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. pubmed.ncbi.nlm.nih.gov
  11. Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015. pubmed.ncbi.nlm.nih.gov
  12. Cardoso LM et al. Acromegaly: biochemical diagnosis. Vitam Horm. 2026. pubmed.ncbi.nlm.nih.gov
  13. Novo Nordisk (DailyMed). Wegovy (semaglutide) label. 2026. dailymed.nlm.nih.gov